Search clinical trials for: AZD5122

Total 99 results

AstraZeneca

Completed

Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects

Healthy

United Kingdom
Peking University
AstraZeneca

Recruiting

Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors

Gastrointestinal Tumors

China
Imperial College London
AstraZeneca; University of Oxford

Active, not recruiting

A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers (COVAXAER01)

Covid19 | SARS-CoV-2 Infection

United Kingdom
AstraZeneca

Completed

AZD1152 in Patients With Advanced Solid Malignancies

Tumors

United States
Ardelyx

Completed

AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study

Healthy Volunteers

United Kingdom
Oxford University Hospitals NHS Trust
University of Manchester; The Christie NHS Foundation Trust; Early Phase Cancer...

Completed

AZD1152 in Diffuse Large B-cell Lymphoma

Lymphoma

United Kingdom
AstraZeneca

Completed

Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia

Myeloid Leukemia

United States, Italy, Netherlands, France
AstraZeneca

Completed

Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)

Acute Myeloid Leukaemia

Japan
AstraZeneca

Active, not recruiting

Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult Participants

COVID-19, SARS-CoV-2

Japan
AstraZeneca

Terminated

AZD1152 in Patients With Advanced Solid Malignancies-Study 1

Solid Tumors

Netherlands
AstraZeneca

Terminated

AZD1152 in Patients With Advanced Solid Malignancies-Study 3

Solid Tumours

United Kingdom
AstraZeneca

Active, not recruiting

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (SUPERNOVA)

COVID-19, SARS-CoV-2

United States, Belgium, Canada, France, Spain, Denmark, Thailand, Vietnam, Korea, Republic of, United Kingdom, Malaysia, Israel, Taiwan, Australia, Germany, Poland, Singapore, United Arab Emirates
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers

Healthy Participants

United States
Ardelyx
AstraZeneca

Completed

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

Type 2 Diabetes Mellitus | Chronic Kidney Disease

United States
AstraZeneca

Completed

A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment

Mild Cognitive Impairment | Mild Alzheimer's Disease

United States
AstraZeneca

Completed

An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)

Acute Myeloid Leukaemia

United Kingdom
AstraZeneca

Completed

Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder

Tourette Syndrome

United States
AstraZeneca

Completed

Study to Investigate Multiple Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects

Healthy

United States
Ardelyx
AstraZeneca

Completed

Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis

End Stage Renal Disease | ESRD | Chronic Kidney Disease Stage 5

United States
AstraZeneca

Active, not recruiting

Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study

COVID-19

United States
Ardelyx

Completed

Dose Finding Study to Treat High Phosphate Levels in the Blood.

Hyperphosphatemia

United States, Poland, United Kingdom, Slovakia
Ardelyx

Completed

A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C (T3MPO-3)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx

Completed

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C (T3MPO-1)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Healthy
Ardelyx

Completed

An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)

Hyperphosphatemia

United States
Ardelyx

Completed

The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Constipation Predominant Irritable Bowel Syndrome

United States
AstraZeneca
RTI Health Solutions

Completed

EU Secondary Data Post-Authorisation Safety Study of AZD1222 (D8111R00006)

COVID-19, Vaccine Adverse Events of Special Interest

Netherlands, Spain, United Kingdom
AstraZeneca

Active, not recruiting

Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19 (NOVELLA)

COVID-19, SARS-CoV-2

Russian Federation
Ardelyx

Completed

A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C (T3MPO-2)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx
AstraZeneca

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects

Healthy Volunteer

United States
AstraZeneca
Covance; Iqvia Pty Ltd

Withdrawn

AZD1222 Vaccine for the Prevention of COVID-19

COVID-19

Russian Federation
AstraZeneca
Parexel

Completed

A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers

Healthy Participants

United States
AstraZeneca

Completed

A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways

Bioavailability and AUC

United Kingdom
Federal University of Espirito Santo
Instituto René Rachou/Fiocruz; Escola Nacional de Saúde Pública Sérgio Arouca... and other collaborators

Recruiting

EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19

SARS-CoV-2

Brazil
AstraZeneca

Completed

Study to Investigate Single Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects

Tolerability

United States
AstraZeneca

Completed

Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Single and Multiple Ascending Oral Doses in Healthy Young and Elderly Japanese Subjects

Healthy

Japan
Ardelyx

Completed

D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects

Healthy Volunteers Food Interaction Study

United States
Chang Gung Memorial Hospital

Recruiting

Immunogenicity of COVID-19 Vaccine on Heterologous Schedule

Healthy | Covid-19 | Vaccine | Immunogenicity | Reactogenicity

Taiwan
Albert B. Sabin Vaccine Institute
Stanford University; Aga Khan University; Oswaldo Cruz Foundation

Completed

Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial

COVID-19

Brazil, Pakistan
AstraZeneca

Completed

Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors

Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor

United Kingdom, United States
AstraZeneca

Completed

Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration

Brain Distribution of [11C]AZ12807110 and AZD5213

Sweden
University of Michigan Rogel Cancer Center

Terminated

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States
AstraZeneca

Completed

AZD5423 Multiple Ascending Dose Study

Healthy

United Kingdom
Humanity & Health Medical Group Limited

Completed

Antibody Response to COVID-19 Vaccines in Liver Disease Patients

Chronic Liver Disease

Hong Kong
AstraZeneca

Completed

AZD5423 Single Ascending Dose Study

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Single and Multiple Dosing of AZD5423 in Japanese Healthy Male Subjects

Healthy

Japan
Federal University of Espirito Santo
Instituto René Rachou/Fiocruz

Recruiting

COVID-19 VACCINE SAFETY AND EFFECTIVENESS

SARS-CoV-2 Infection

Brazil
AstraZeneca

Not yet recruiting

A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure (LUMINARA)

Chronic Heart Failure
AstraZeneca
Iqvia Pty Ltd

Completed

Study of AZD1222 for the Prevention of COVID-19 in Japan

COVID-19

Japan
R-Pharm
AstraZeneca; Russian Direct Investment Fund; The Gamaleya National Center of...

Completed

Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19

COVID-19

Russian Federation

3

Subscribe